CEO Kevin Ali resigned following an internal investigation into Nexplanon sales practices and the board named manufacturing head Joseph Morrissey as interim CEO. Although the board noted limited financial impact, the leadership change highlights an intensified focus on strengthening internal controls and financial reporting procedures.

In the fourth quarter of 2025, total revenue declined year-over-year as the women's health segment contracted while biosimilars saw modest growth, non-GAAP gross margins narrowed, and the company incurred a net loss driven by a non-cash goodwill impairment. For the full year, Organon reported $6.216 billion in revenue (down 3%) and $1.907 billion in adjusted EBITDA (30.7% margin), and guided 2026 revenue and EBITDA to remain flat with 2025 levels.

In 2025, Established Brands produced $3.691 billion of revenue but fell 4% due to pricing pressures and loss of exclusivity on key products such as Atozet. Women's Health revenue declined 4% ex-FX with Nexplanon volumes down 4% overall and 9% in the U.S., while biosimilars rose 4% driven by Hadlima, though pricing erosion in mature molecules poses ongoing headwinds.